1. Scrip

Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021

 
• By Jessica Merrill

HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.

Kidney Disease - Printed Diagnosis with Red Pills, Injections and Syringe. Medical Concept with Selective Focus.
Akebia hoped vadadustat would show a safety benefit in non-dialysis CDK versus ESAs • Source: Shutterstock

Akebia Therapeutics, Inc../Otsuka Pharmaceutical Co. Ltd.'s Phase III program for vadadustat disappointed in patients with anemia due to chronic kidney disease (CKD) who aren't on dialysis, setting up a more challenging road to approval in a broad CKD setting. The companies announced mixed data from the two trials on 3 September.

More from Genitourinary

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.